AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

CPHI & PMEC China 2026 is set to take place from 16 to 18 June 2026 at the Shanghai New International Expo Centre (SNIEC), ...

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai ...

BOCA RATON, Fla.--(BUSINESS WIRE)--LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product life cycle, today reported that its unique mix of active pharmaceutical ...

Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market for pharma companies.

While solely API-focused players currently face increased competition, this transition is expected to strengthen long-term pricing power, improve margins, enhance compliance, and increase customer ...

The genesis of a small molecule drug is often an international affair. The medication might begin its life at an active pharmaceutical ingredient (API) manufacturing facility in Puerto Rico, then stop ...

DUBLIN, May 10, 2021 /PRNewswire/ -- The "Global Active Pharmaceutical Ingredient Market (2020-2025) by Type, Molecule, Product Type, Formulation Type, Manufacturing Type, Synthesis Type, Drug Type, ...

India hosts more active pharmaceutical ingredient (API) manufacturing sites that are compliant with the U.S. Food and Drug Administration than any country outside the U.S., and it produces more ...